Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

858
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
858
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.6K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.6K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

208
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
208

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Kaposiform vascular tumors with Kasabach-Merritt phenomenon: a case series of KHE and KLA from a tertiary care center in India.

European journal of pediatrics·2026
Same author

Prospective Collaborative Study for Pulse Dexamethasone and Lenalidomide in Relapsed/Refractory Langerhans Cell Histiocytosis (LENDEX-LCH Study): INPHOG-HIST-19-03 (CTRI/2020/07/026937).

Pediatric blood & cancer·2026
Same author

Short, safe, and sustainable: outpatient blinatumomab as a bridge and beyond in children with pre B-acute lymphoblastic leukemia.

Leukemia & lymphoma·2026
Same author

Long term outcomes of the Indian childhood cancer survivorship (C2S) cohort: a multicentre study (2016-2024).

The Lancet regional health. Southeast Asia·2026
Same author

Correction to: An international survey of allogeneic hematopoietic cell transplantation for X-linked agammaglobulinemia.

Journal of clinical immunology·2026
Same author

Common Variable Immunodeficiency Disorder: A Decade of Insights from a Cohort of 150 Patients in India and the Use of Machine Learning Algorithms to Predict Severity.

Journal of clinical immunology·2025

相关实验视频

Updated: Jan 13, 2026

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

12.1K

在接受癌症化疗和血造干细胞移植的儿童严重心脏功能障碍中,Levosimendan的有效性和安全性.

Rachit Mehta1, Indira Jayakumar1, Prasad Manne2

  • 1Department of Pediatric Onco-Critical Care, Apollo Hospitals, 320, Padma Complex, Anna Salai, Teynampet, Chennai, 600035 India.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
|January 12, 2026
PubMed
概括
此摘要是机器生成的。

利沃西门丹在接受化疗或干细胞移植的儿科癌症患者中有效治疗心脏功能障碍. 这种心脏保护药物改善了心脏功能,并维持了年轻患者的正常血压.

关键词:
癌症 癌症 癌症 癌症心脏功能障碍是因为心脏功能障碍.孩子 孩子 孩子 孩子这就是HSCT的特点.您的位置 首页 您的位置

更多相关视频

Cardiac Spheroids as in vitro Bioengineered Heart Tissues to Study Human Heart Pathophysiology
10:41

Cardiac Spheroids as in vitro Bioengineered Heart Tissues to Study Human Heart Pathophysiology

Published on: January 23, 2021

8.2K
Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
08:47

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes

Published on: December 16, 2022

2.8K

相关实验视频

Last Updated: Jan 13, 2026

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

12.1K
Cardiac Spheroids as in vitro Bioengineered Heart Tissues to Study Human Heart Pathophysiology
10:41

Cardiac Spheroids as in vitro Bioengineered Heart Tissues to Study Human Heart Pathophysiology

Published on: January 23, 2021

8.2K
Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
08:47

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes

Published on: December 16, 2022

2.8K

科学领域:

  • 儿童心脏病学 儿童心脏病学
  • 在瘤学瘤学.
  • 关键护理医学 关键护理医学

背景情况:

  • 与癌症治疗有关的心脏功能障碍是儿科血液瘤学中一个关键的,经常被忽视的问题.
  • 莱沃西门丹因其心脏保护潜力在儿科急诊护理中得到了探索.

研究的目的:

  • 评估levosimendan在接受化疗或HSCT的心脏功能障碍的儿科患者的疗效和安全性.
  • 评估levosimendan作为一线和二线心脏支持剂的有效性.

主要方法:

  • 从2020年1月到2023年12月,对62名儿童 (18岁以下) 进行了回顾性研究.
  • 莱沃西门丹作为一线治疗已知的功能障碍和二线治疗具有功能障碍的休克药物.
  • 通过射出分数,血管活性-内热学评分 (VIS) 和心声回声 (ECHO) 评估有效性.

主要成果:

  • 在儿科患者中观察到85%的整体应答率.
  • 平均喷射分数从50%提高到58%.
  • 平均VIS减少3.2;随访时心脏功能正常ECHO在四周.

结论:

  • 利沃西门丹是一种安全有效的治疗急性心力衰竭的儿童血液瘤学患者,血压保持.
  • 结果有助于为患有心脏功能障碍的儿科血液瘤患者量身定制关键护理.